At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,680 enrolled
Drug / intervention
QIVc +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age
In Brief
A Phase 3 clinical trial evaluating QIVc, TIV1c, and 1 other intervention for Influenza. Completed, enrolled 2,680 participants across 40 sites.
Detailed Summary
Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionJul 2014
TodayJul 2026
First PostedNov 25, 2013
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.6 years ago
Interventions
QIVcbiological
Novartis Investigational Quadrivalent Vaccine
TIV1cbiological
Licensed Influenza Vaccine
TIV2cbiological
Novartis Investigational Vaccine